Lenograstim is a granulocyte colony-stimulating factor indicated in the reduction of duration of neutropenia in bone marrow transplant and cytotoxic chemotherapy, as well as mobilizing hematopoietic stem cells in healthy donors. A medication used to stimulate the immune system in patients who have had a bone marrow transplant.
- Mechanism
- Curator reviewed
Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. Lenograstim accelerates neutrophil recovery significantly after chemotherapy, with beneficial effects on clinical end-points such as incidence of laboratory-confirmed infection and length of hospital stay. Chemotherapy dose intensity has also been increased in patients receiving lenograstim, notably those with breast or small cell lung cancer, although improvements in tumour response and survival have not been demonstrated. Lenograstim also assists neutrophil recovery in patients undergoing bone marrow transplantation, and stimulates the production of peripheral blood stem cells (PBSCs) for autologous transfusion after aggressive chemotherapy.
- Primary indication
- The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.Curator reviewed · 3 structured indications
- Also known as
- Lenograstim (genetical recombination) · Lenograstim rDNA
Resolves to
What you can answer from here — as of July 20, 2026
Which drugs share a target with Lenograstim, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account